Health Robotics Releases Results of First 20 i.v.STATION's Return On Investment (ROI) Studies in the USA and Canada
BOZEN, SUD-TIROL, Italy, September 8, 2010 /PRNewswire/ -- Health Robotics released the results of the first 20 financial i.v.STATION studies conducted by selected North American channel partners at various Academic, Community, Pediatric, and Oncology hospitals in Alabama, California, Florida, Illinois, Louisiana, Massachusetts, Michigan, Ohio, Ontario, Pennsylvania, Quebec, and Texas. These studies compared the direct costs of i.v.STATION-produced sterile doses to compounded IVs manufactured by 6 Pharmacy Outsourcing and Pre-Mix/Frozen solutions companies. Health Robotics' web-registered authorized users may access i.v.STATION's ROI case studies and custom Microsoft Excel tools at http://www.health-robotics.com/en/solutions/i-v-station/
"i.v.STATION's $300,000 price, combined with its plug-and-play installation, flexibility of IV Bags/Vials/Syringes, ISO-5 controlled environment, and unprecedented robotic throughput, has already revolutionized Non-Hazardous Sterile Compounding in North America. Multiple hospital studies have proven an i.v.STATION's 3-to-1 cost advantage over Pre-Mix/Frozen solutions by Baxter, B. Braun, and Hospira, resulting on an average 8-month payback period to American hospitals utilizing between 1,200 and 1,400 median Minibag Plus, Duplex, or ADD-Vantage IV doses per month. As many North American hospitals have lately been forced towards increased IV Outsourcing as a result of recent IV drug shortages, i.v.STATION arrives at the right place and at the right time, offering a much more cost effective solution to the widespread scarcity problem in selected antibiotics, pain therapy, and other IV drug classes, while providing Health-System Pharmacies with much more control over Batch IV production and reduced IV waste," stated Gaspar DeViedma, Health Robotics' Executive Vice President.
i.v.STATION represents a revolutionary approach in the quest for safe, accurate, efficient, cost effective, and ready-to-administer intravenous patient doses. i.v.STATION offers unprecedented reduction of IV medication errors, USP 797 compliance, compatibility with 75+ different Syringe and IV Bags brands/sizes, reduction of IV waste, and significant labor savings: all within a scalable, cost-effective, distributed, and fail-safe architecture.
"i.v.STATION has also consistently revealed a 6-to-1 cost advantage over outsourced custom IV manufacturing offered by Ameridose, CAPS, and PharMEDium in multiple North American local markets, yielding an average 6-month payback period to North American Health-System Pharmacies that typically custom-outsource between 600 and 800 IV doses per month, and a 12-month payback period for those hospitals outsourcing approximately 350 IV doses per month. These outstanding results amply justify Health Robotics' prior announcement that it had ended its 2010 i.v.STATION early-adopter discount program in North America this Summer. It is extremely rare these days to find technologies with hard-dollar cost-justification cycles of less than 12 months. We look forward to continue these studies over the next three months at North American Health-Systems that exclusively compound sterile IV doses in-house without custom-IV-outsourcing or Pre-Mix solutions.", concluded Mr. DeViedma.
About Health Robotics:
Health Robotics is the undisputed global leading supplier of life-critical intra-venous medication robots, providing over 160 hospital installations in 5 continents with robotics technology and software automation solutions deployed utilizing virtual high-availability technology. Its world-leading solutions CytoCare(TM) [hazardous IVs], i.v.STATION(TM) [non-hazardous IVs], i.v.SOFT(TM) [manual compounding software], MEDarchiver(TM) [life-critical clinical information system], and TPNstation(TM) [totally-automated parenteral nutrition] have and will greatly contribute to ease hospitals' growing pressures to improve patient safety, increase throughput and contain costs. Through the effective and efficient production of sterile, accurate, tamper-evident and ready-to-administer IVs, Health Robotics' solutions help hospitals eliminate life-threatening drug and diluent exchange errors, decrease other medical mistakes and sterility risks, work more efficiently, reduce waste and controlled substances' diversion, and diminish the gap between rising patient volume/acuity and scarce medical, nursing, and pharmacy staff. For more information, please visit: http://www.health-robotics.com
For additional information, please contact: Claudia Flaim, Marketing Coordinator Altmanstrasse 9/A, Bozen, I-39100 [email protected] Phone: +39-0471-200-372
SOURCE Health Robotics
Share this article